Tvardi Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a hold rating in a research report sent to investors on Sunday.

TVRD has been the subject of several other research reports. Cantor Fitzgerald cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. BTIG Research lowered their target price on Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a report on Monday, October 13th. Barclays set a $5.00 target price on Tvardi Therapeutics and gave the company an “equal weight” rating in a research report on Monday, October 13th. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 15th. Finally, Raymond James Financial cut Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Tvardi Therapeutics presently has an average rating of “Hold” and a consensus price target of $55.50.

Tvardi Therapeutics Trading Up 0.5%

TVRD opened at $4.00 on Friday. The business’s fifty day simple moving average is $4.45 and its 200-day simple moving average is $20.02. The company has a market capitalization of $37.52 million, a price-to-earnings ratio of -0.42 and a beta of 0.11. Tvardi Therapeutics has a 12-month low of $3.74 and a 12-month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24. Tvardi Therapeutics had a negative net margin of 585.37% and a negative return on equity of 282.16%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TVRD. JPMorgan Chase & Co. purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Tvardi Therapeutics during the second quarter worth about $43,000. Headlands Technologies LLC purchased a new position in Tvardi Therapeutics during the second quarter valued at approximately $80,000. New York State Common Retirement Fund purchased a new position in Tvardi Therapeutics during the second quarter valued at approximately $92,000. Finally, Squarepoint Ops LLC acquired a new position in Tvardi Therapeutics in the third quarter valued at approximately $318,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.